GOAL

Update an existing website and prepare the transition from a private company to an IPO.

SOLUTION

325 moved the outdated initial website from Squarespace to a more functional WordPress platform to scale for an IPO. We leveraged existing brand guidelines and elevated to position effectively to their target audience. 325 pivoted with urgency multiple times to address their needs.

We designed and developed a customized website and set up to keep the brand intact on each web page so it would smoothly transition to NASDAQs IR/IPO platform versus damaging brand consistency.

DELIVERABLES

BRAND STRATEGY
WEBSITE DESIGN + DEVELOPMENT
IR/IPO WEBSITE TRANSITION

VIEW WEBSITE

STRATEGY

325 analyzed the old site and the existing brand guidelines and discovered a huge disconnect. As result, we sought to integrate the existing brand guidelines in the new website and complimented and elevated the tone and feel with high-quality stock photography to more align with the life science technology offering.

We built the website on a WordPress platform which provided endless flexibility and adaptability to pivot based on the company’s needs. At the height of Covid-19, messaging shifted to address Angion’s lung therapies and position the company as a leader for acute lung injury as it related to a possible cure for Coronavirus disease at the time. Every messaging update coincided with updates to the website.

To maintain brand consistency and maintain web design intact, we worked with the Intrado investor relations platform and transitioned Angion’s website preparing them for an IPO. Each page was designed, built and provided to Intrado to follow lead verse being forced into a cookie-cutter template for a novel, unique brand.

325 designed Angion’s social media platforms and worked with LifeSci to push out press releases and then activated the site. 325 served as a remote creative and marketing team thereafter and provided a turnkey response, even overnight on weekends, to accommodate needs during the pre IPO and IPO stages.

INVESTOR RELATIONS

Our team works in tandem with our client’s investor relations partner and integrates the overall brand to the IR portion of the website.

ABOUT ANGION BIOMEDICA CORP.

Angion (NASDAQ: ANGN) is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases.

ADDITIONAL CASE STUDIES

Click an image below to view more case studies.